Background and Aims HIV infection and mortality in Eastern Europe are driven by unsafe injection drug use. We
INTRODUCTION
Recent efforts to control HIV epidemics have emphasized the need to improve linkage to care and adherence to highly active antiretroviral therapy (HAART) among people living with HIV infection [1] . The treatment cascade has been used to identify gaps in the steps needed to improve the health of people living with HIV (PLWH) and prevent further transmission [2, 3] . Barriers to engagement within the cascade of HIV care have been identified for different populations [4] [5] [6] [7] [8] . In the United States the cascade has been analyzed to consider age, race, sex, and risk factors [9] . Social-ecological factors of engagement in care have been explored and their importance in creating targeted prevention approaches demonstrated [10, 11] . Most of the studies described have been based on the secondary data analysis [12, 13] or retrospective cohort studies [14] , focusing on different stages of the cascade. Such data are less available to estimate HIV care engagement in hard-to-reach and understudied populations. Despite the challenges in building HIV treatment cascades that include variations in metrics, contextual influences [15] and missing outcomes [5] , it is important to expand the use of the treatment cascade to inform and improve HIV epidemic control and increase engagement in care.
Our study sought to assess engagement in HIV care among people who inject drugs (PWID) in Kohtla-Järve in northeastern Estonia and the Russian city of St Petersburg, two neighboring regions in countries with high HIV prevalence [16, 17] . The two regions share a common history as part of the USSR when HIV surveillance was initiated in the late 1980s, and both experienced serious social-economic challenges and major transitions in health care after the collapse of the USSR in 1991. Twin epidemics of injection drug use and HIV emerged at a similar moment later in the decade [18, 19] .
The study context: HIV in Russia and Estonia
In 2014 Russia and Estonia reported the first and third highest HIV numbers of newly diagnosed HIV cases in Europe: 82.4.1/100 000 and 29.6/100 000, respectively [20, 21] . Country-wide HIV prevalence in PWID is estimated 53% in Estonia and 16% in Russia [22] , although in some regions of Russia, including St Petersburg, prevalence exceeds 50% [23] . There are, however, substantial differences between the responses in the two countries.
HIV in Russia is now estimated to infect 0.8-1.4% of the total population, with more than 1 000 000 officially registered cases and greater than 10% increases in the number of new diagnoses every year since 2012 [17, 23] . Although epidemic control efforts include free HIV testing, health care, treatments and social welfare services that are guaranteed to all citizens of Russia, effective control measures targeting the most at-risk population of PWID have not been implemented. Standard international harm reduction approaches are limited. Opioid substitution therapy remains illegal, while needle and syringe program coverage is sparse and operates almost exclusively through non-governmental organizations, with minimal political and financial support [24, 25] . Only 120 000 PLWH were provided treatment in 2013, reaching fewer than 20% of those in need [17] . The mandate that people with a history of injection drug use be 6 months drug-free prior to the initiation of HAART has prevented initiation of treatment among PWID, and it has been estimated that only 1% of HIV-positive PWID receive HAART [25] [26] [27] .
Conversely, in Estonia the system of care has gone through the set of significant changes and has reformed its health system successfully [18, 28] . Capacity building for the governmental and non-governmental sectors to interact constructively with each other has been instrumental in this process [29] . Estonia has increased its capacity to manage its response to HIV/AIDS during the past decade by scaling-up syringe exchange programs and establishing opioid substitution-based drug treatment. Nevertheless, in 2012 HIV population prevalence in Estonia was 1.3%, the highest in Eastern Europe [28] . Among PWID, the estimated incidence in Tallinn, the capital, was still 7.5/100 person-years in 2011 even though 40% of all HIV-positive individuals were receiving care [30] .
The analysis presented in this paper seeks to update estimates of PWID engagement in care in contiguous regions of the two countries-St Petersburg and KohtlaJärve. We have created treatment cascades for the two sites, relying upon an integrated biobehavioral survey conducted at both sites in 2012-13 using similar methods, and identified associated social-behavioral barriers at each step in the treatment cascade, stratified by site, to identify factors amenable to remediation specific to each location. Thus, this study had two aims: (1) To compare progress along the cascade in the two regions; and (2) To produce a model of the factors significantly associated with progression at each step in the cascade.
METHODS

Study-site specifics
St Petersburg is the largest northern city in Europe, with a population of more than 5 000 000 people, and the second most important political, social, cultural and industrial center in Russia. It consists of 18 districts containing the historical and business center, industrial areas, and outlying residential districts spread along the coast of the Gulf of Finland. Some districts are as much as a 2-hour ride on public transportation from the city center. In St Petersburg at the time of the study, AIDS treatment for St Petersburg residents was offered free of charge at two centrally located facilities, the City AIDS Center and Botkin Infectious Disease Hospital. Decisions concerning the initiation of HAART were made by a committee of physicians and support staff once a patient's CD4 + cell count was ≤ 350 cells per μl. Kohtla-Järve is an administrative center in Ida-Viru County in northeastern Estonia that borders on the northwestern administrative region of Russia, which is centered in St Petersburg. It consists of six districts that historically contained farmlands and chemical industrial areas adjacent to shale oil mines. Post-Soviet collapse of these industries has resulted in a declining population that is now 37 000, down from 90 000 in 1990. The vast majority of the population migrated from other parts of the Soviet Union to Kohtla-Järve to work in these industries, and the population remains ethnically Russian, with Russian spoken most commonly. At the time of the study, AIDS treatment was provided by the government 
Socio-behavioral data collection
Surveys were conducted to collect socio-demographic, behavioral, health services, knowledge, attitude and perceptions data through face-to-face interviews conducted at or near recruitment sites in St Petersburg and at the exchange site in Kohtla-Järve. The survey instrument was based on World Health Organization (WHO) Drug Injecting Study Phase II questionnaire (version 2b, revision 2) [33] and modified by agreement among members of the international research team. The survey was adjusted later for use in St Petersburg by adding additional questions. At both sites the questionnaire included the following sections: RDS-related questions, socio-demographics, tobacco, alcohol and injectable psychoactive drug use, injection-related HIV risks, sexual behaviors, HIV/AIDS, hepatitis and overdose knowledge, overdose history, physical and mental wellbeing, drug and HIV treatment experiences, incarceration history, the use of somatic and mental health, harm reduction and social care services, HIV-disclosure and status stigma related to either injection drug use or HIV infection. Alcohol misuse used the Russian-validated CAGE (Cut-down, Annoyed, Guilt, Eye-opener) questionnaire [34, 35] and three questions concerning quantity and frequency of drinking [36] . Problematic alcohol consumption was defined as > 14 drinks per week for men or > 7 drinks per week for women with a CAGE score 1 or a CAGE score of ≥ 2. Internalized and anticipated stigma measures were adopted from Kalichman et al. and Pinel, respectively, and as adapted as described in Burke et al. [37] [38] [39] .
HIV testing
Testing in St Petersburg used Orasure rapid oral antibody tests (OraSure Technologies, Inc., Bethlehem, PA, USA). Study participants who tested positive were referred for confirmatory testing to the St Petersburg AIDS Center. In Kohtla-Järve, serum samples obtained by venipuncture were tested using commercially available kits for HIV antibodies (ADVIA Centaur HIV Antigen/Antibody Combo Assay, Siemens Healthcare Diagnostics, Erlangen, Germany).
Cascade steps
Data from the survey were used to construct a six-state, five-step treatment cascade based on self-report from participants who tested positive for HIV when recruited into the study. Data for the cascade were obtained by self-report from all participants in each location who tested positive for HIV at enrolment in the study.
Step 1 HIV testing coverage was determined through the use of a question about ever having been tested for HIV.
Step 2 HIV-diagnosed indicates, among those ever tested for HIV, those who were aware of their HIVpositive status before they took part in our study. This required a response of HIV-positive to a question about the result of the respondent's last HIV test.
Step Kohtla-Järve were more likely to be younger, married, living with their children, have only a basic secondary school education, receive financial subsidies from family or the state, have difficulty in coping financially and have been incarcerated. Differences were detected in two of five drug use-related services. HIV-positive PWID in KohtlaJärve were more likely to be receiving treatment for drug abuse and more likely to use services offered by syringe exchange programs (Table 1) . Differences were also detected on three of four stigma-related variables. HIVpositive PWID in Kohtla-Järve reported significantly lower stigma regarding internalized stigma for both HIV and injection drug use and regarding anticipated stigma for injection drug use ( Table 1 ).
The five-step treatment cascade comparing the two locations is depicted in Fig. 1 More than 95% of each sample reported having been tested for HIV-1. For those who tested HIV-positive, 3.8% in Kohtla-Järve and 3.3% in St Petersburg had never been tested previously (step 1, Fig. 1) . However, only 85% of the HIV-positive sample in St Petersburg and 78.1% in Kohtla-Järve reported being aware of a positive test result. A significantly smaller percentage of people in Kohtla-Järve made the transition from having been tested to being aware of their infection (step 2, Fig. 1 ). In bivariate analysis, there were two common factors associated with being aware of a positive HIV-1 test result in the two locations and some that were identified only in Kohtla-Järve (Table 2 ). Higher frequencies of alcohol use and drug injection were associated with being aware of the HIV-positive status. While no additional factors associated with an increased likelihood of being aware of a positive test result were identified in St Petersburg, several were in Kohtla-Järve. These included having no legal income, not being married, having been incarcerated and having lower anticipated stigma regarding injection drug use ( Table 2) .
Success in achieving the next step in the cascade, receiving regular HIV care, was far more common in Kohtla-Järve than in St Petersburg (Figure 1, step 3) . In Kohtla-Järve, 73% PWID made this transition, whereas in St Petersburg only 32% did so. Factors in bivariate analysis associated with successful transition to care in both locations included having basic medical insurance, fewer injections both in terms of number of times per day and number of days in the month prior to interview, obtaining financial support from others and being in drug treatment (Table 3) . High alcohol consumption and daily tobacco use were more likely among PWID who failed to seek regular treatment in St Petersburg. Also associated with failure to seek regular treatment in St Petersburg were several measures of stigma, including anticipated stigma for HIV and internalized stigma for both HIV and injection drug use (Table 3) .
Although national guidelines at the time of the study did not specify that all HIV-positive individuals should be receiving HAART, we determined the proportion of those in regular care who had been offered an opportunity to initiate HAART. The proportion was significantly higher in Kohtla-Järve (74%) than in St Petersburg (45%) (step 1). Comparison of the factors associated significantly with being offered HAART revealed no overlaps between the two sites (Table 4 ). In Kohtla-Järve, living with a person Scores for anticipated stigma for injection drug use were based on six questions, scored 0-4 for a range of 0-30, where a higher score was indicative of greater stigma.
of the opposite sex and not having insurance were associated with not having been offered HAART. In St Petersburg there were differences in the types of drug injected, while injecting on more days in the past month was associated with not having been offered HAART.
Finally, we found that similar percentages of those offered HAART were receiving it (77% in both locations) (step 1). However, the overall percentage of HIV-positive PWID who were receiving HAART in St Petersburg was only a third of those Kohtla-Järve. This was also true when restricting the analysis to those HIV + PWID who were aware of being infected. We could identify no factors in St Petersburg or Kohtla-Järve that distinguished those receiving HAART from those offered but not receiving it.
We developed multivariate models to determine which of the factors, significant in the bivariate analyses, remained associated with steps 2, 3 and 4 in the cascade. These analyses were hampered by the decreasing sample size with each step in the cascade. This was especially true in St Petersburg, where only step 3, the transition from receiving a positive diagnosis and being in regular HIV care, yielded significant covariates. Here, injecting on fewer days (adjusted odds ratio of 0.953; 95% CI = 0.920-0.987) and higher internalized stigma (adjusted odds ratio of 1.072; 95% CI = 1.015-1.133) remained significantly associated (AIC = 284.2). In Kohtla-Järve we identified significant covariates for each of the three steps (Table 5 ). For step 2 (awareness of a positive diagnosis) the drug and alcohol use variables remained associated significantly. There are difference in drug markets between the two cities. In Kohtla-Järve, the main opioids are fentanyl and its derivative; in St Petersburg, the main opioids are heroin and methadone. For step 3 (receiving regular HIV care) medical insurance and three variables related to drug use remained significant. For step 4 (receiving an offer to initiate HAART) having insurance remained significant, as was living with a sex partner.
DISCUSSION
The driving force of HIV infection at the population level in Estonia and Russia remains transmission among PWID and thence sexual transmission from PWID to their partners. The surest route to epidemic control is to focus efforts on controlling HIV spread in these populations. A major goal for epidemic control would be reduction in community viral load through universal provision of effective antiretroviral therapy. As noted by Risher et al., such efforts must include analysis of the cascade in key populations in order to reach those most at risk [41] .
In this paper, we analyzed the HIV care cascade among PWID, demonstrating that engagement in HIV care among large samples of PWID in Kohtla-Järve and St Petersburg is further along in Kohtla-Järve. Overall, approximately one in three HIV-infected PWID in Kohtla-Järve versus only one in 10 in St Petersburg was receiving antiretroviral medications in 2012. Both numbers will need to increase for epidemic control. At the level of specific steps, our analysis has identified those steps that see the greatest failure to progress and produced multivariate models that have identified key factors associated with failure to progress along the cascade.
The first step with substantial failure to progress is the transition from having ever been tested to knowing that one is HIV infected. However, our cross-sectional study design does not allow us to distinguish between three alternative reasons: is the failure due to an infection since the last test, an individual's reluctance to obtaining a test result or a system failure to inform individuals of an HIVpositive test result? Regardless of the reason, closing this gap will require providing more frequent HIV testing that includes a concerted effort at post-test counseling and referral to care. Efforts to increase awareness common to both locations could include making special efforts to test and counsel individuals whose alcohol consumption is problematic. The association of increasing injection frequency with receiving an HIV-positive diagnosis could have many causes, but our study was not designed to distinguish between alternatives.
The next major step with substantial failure to progress is the transition from receiving a positive diagnosis to being in regular care. Among PWID aware of being infected, engagement in regular care at stage 4 in Kohtla-Järve was more than twofold greater than in St Petersburg. Because St Petersburg is far larger than Kohtla-Järve, it is possible that the shorter distance to care services might explain the greater access in Kohtla-Järve. To address this issue, we conducted a spatial analysis to determine if proximity of residence to existing care facilities in St Petersburg was associated with more engagement, but we could not detect any significant associations (data not shown); nor were residential locations a significant factor associated with any other step in the cascade. Previous work has suggested that stigma and strength of the patient-physician bond can play important roles in accessing and remaining in HIV care [37, 42] . This study adds additional factors that appear to influence this step, including drug use, drug treatment and medical insurance.
Higher proportions of PWID were offered and were receiving HAART in Kohtla-Järve than in St Petersburg. In Kohtla-Järve, medical insurance and not living with a partner were associated with receiving HAART, whereas in St Petersburg drug use factors predicted transition to receiving care but not HAART.
There were several disparate findings. The first concerns injection drug use, which is often held to hamper retention in HIV care. Variables measuring the intensity of drug use were associated with a higher likelihood of having received an HIV-positive diagnosis (step 2), but were associated with decreased receipt of ongoing HIV care, and in St Petersburg with a decreased likelihood of having been offered HAART. The second concerns stigma, which is also thought to present barriers to engagement in HIV care. We found that, of the four stigma variables, only higher anticipated stigma for injecting was associated with receiving a positive diagnosis, and only in Kohtla-Järve. This association, contrary to expectations, suggests a level of stigma resilience in the Estonian sample, perhaps resulting from the increased efforts to engage PWID in HIV prevention and treatment.
This study has limitations due to sampling and the use of self-reported data for everything but current HIV serostatus. Sampling of PWID cannot be performed at random, and although RDS is used to reach across multiple networks of PWID, there is no guarantee that the sample is representative of the underlying population. Therefore, it is not possible to generalize our results to PWID in other locations or even to all PWID in the two locations studied. The findings reported for PWID in the two locations cannot be generalized to other regions of Russia or Estonia. Nevertheless, each of these two locations has the highest HIV prevalence within its country and each is burdened by a large population of PWID. As this study is, to our knowledge, the first to explore the HIV treatment cascade for HIV-positive PWID in the two countries, it sets a benchmark against which other studies exploring engagement in HIV care in the two countries can be compared, consistent with recommendations developed recently for studying the cascade [43] . Another limitation is that self-reported data are insufficient to learn about the next step in the treatment cascade: has HAART resulted in undetectable viral loads? For this we would need medical chart data, which were not possible to obtain as participation was anonymous. Conversely, using survey data from samples recruited outside the treatment setting is the most efficient way to study the early steps in the cascade [44] . Another limitation is based on the decision to analyze the data as contingent, i.e. only those who have completed the prior step were considered in the next step. This may introduce a bias regarding the composition of the remaining subsample. A separate analysis might reveal factors other than those we identified that differentiate the entire sample of PWID from those achieving a given step in the cascade. However, this report is focused upon identifying factors associated with success or failure in making each transition, which is important in guiding HIV care providers as they seek to move their patients along the cascade to the end goal of viral load suppression.
